Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Phosphatase and tensin homolog accelerate the inflammatory injury and glycolysis of chondrocytes through TP53 protein-mediated p38MAPK pathway activation in a high-glucose environment

Ding J., Yang C., Li X.

Laboratory Study on Osteoarthritis, published in Cytojournal (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cytojournal (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41216229
PMCID
PMC12596799
DOI
10.25259/cytojournal_199_2024

Abstract (original English)

Objective Chronic metabolic diseases represent a high-risk factor for osteoarthritis. In particular, diabetes has been proven to be closely related to the occurrence of osteoarthritis in cases called diabetic osteoarthritis (DAO). A large number of studies have shown that phosphatase and tensin homolog (PTEN) are involved in the progression of osteoarthritis; however, the mechanism of PTEN in DAO remains unclear. Accordingly, this study aimed to explore the regulatory role of PTEN in inflammatory injury and glycolysis during the progression of DAO. Material and methods Primary chondrocytes treated with high glucose (HG) were transfected with the small interfering (si) RNA of PTEN or tumor suppressor protein p53 (TP53). Then, cell viability and apoptosis, inflammatory factor secretion, and the protein expression of matrix metalloproteinase 13 and collagen II were detected. Subsequently, we examined glucose uptake, lactate production, reactive oxygen species (ROS) content, and the protein expression of glycolysis-related molecules, namely hexokinase2 and lactate dehydrogenase A, in PTEN knockdown primary chondrocytes. Then, primary chondrocytes were transfected with siRNA against PTEN (siPTEN) alone or together with plasmid DNA (pcDNA)-TP53 to detect changes in cellular inflammatory damage and glycolysis, and thus, determine whether the p38 mitogen-activated protein kinase (p38MA

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research